ArticleiScience2022
Immunity to SARS-CoV-2 up to 15 months after infection.
Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Cancer viroimmunotherapy platforms based on varicella-zoster virus and cytomegalovirus.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Role of vaccines in competitive displacement between SARS-CoV-2 viruses as revealed by the modeling of surveillance data.Infection · 2025Article
- Dysregulated Adaptive Immune Responses to SARS-CoV-2 in Immunocompromised Individuals.Microorganisms · 2025Article
- Article
- Polyfunctional T peripheral helper cells are associated with the magnitude and durability of antibody responses after COVID-19.Clinical & translational immunology · 2025Article
- Article
- Enhanced RBD-Specific Antibody Responses and SARS-CoV-2-Relevant T-Cell Activity in Healthcare Workers Following Booster Vaccination.Current issues in molecular biology · 2024Article
- SARS-CoV-2-Specific T-Cell as a Potent Therapeutic Strategy against Immune Evasion of Emerging COVID-19 Variants.International journal of molecular sciences · 2024Article
- Review
- Frequency of SARS-CoV-2 Infections among Healthcare Workers in Germany: 3-Year Follow-Up Study.Infectious disease reports · 2024Article
- Comparative single-cell transcriptomic profile of hybrid immunity induced by adenovirus vector-based COVID-19 vaccines.Genes and immunity · 2024Article
- A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants.Frontiers in immunology · 2024Article
- Design, structure and plasma binding of ancestral β-CoV scaffold antigens.Nature communications · 2023Article
- SARS-CoV-2 spike-specific TSignal transduction and targeted therapy · 2023Article
- Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020-2022): A retrospective longitudinal SARS-CoV-2 serological surveillance.Human vaccines & immunotherapeutics · 2023Observational
- Article
- Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals.PloS one · 2023Article
- SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients.Frontiers in immunology · 2023Article
- COVID-19 immunopathology: From acute diseases to chronic sequelae.Journal of medical virology · 2023Review
- Defending against SARS-CoV-2: The T cell perspective.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Information concerning the longevity of immunity to SARS-CoV-2 following natural infection may have considerable implications for durability of immunity induced by vaccines. Here, we monitored the SARS-CoV-2 specific immune response in COVID-19 patients followed up to 15 months after symptoms onset. Following a peak at day 15-28 postinfection, the IgG antibody response and plasma neutralizing titers gradually decreased over time but stabilized after 6 months. Compared to G614, plasma neutralizing titers were more than 8-fold lower against variants Beta, Gamma, and Delta. SARS-CoV-2-specific memory B and T cells persisted in the majority of patients up to 15 months although a significant decrease in specific T cells, but not B cells, was observed between 6 and 15 months. Antiviral specific immunity, especially memory B cells in COVID-19 convalescent patients, is long-lasting, but some variants of concern may at least partially escape the neutralizing activity of plasma antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.